|
| Primary information |
|---|
| ID | 11716 |
| Therapeutic ID | Th1253 |
| Protein Name | Hyaluronidase (ovine) |
| Sequence | >Th1253_Hyaluronidase_(ovine)
MWTGLGPAVTLALVLVVAWATELKPTAPPIFTGRPFVVAWDVPTQDCGPRHKMPLDPKDMKAFDVQASPNEGFVNQNITIFYRDRLGMYPHFNSVGGSVHGGVPQNGSLWVHLEMLKGHVEHYIRTQEPAGLAVIDWEDWRPVWVRNWQDKDVYRRLSRQLVASHHPDWPPERIVKEAQYEFEFAARQFMLETLRFVKAFRPRHLWGFYLFPDCYNHDYVQNWETYTGRCPDVEVSRNDQLSWLWAESTALFPSVYLEETLASSTHGRNFVSFRVQEALRVADVHHANHALPVYVFTRPTYSRGLTGLSEMDLISTIGESAALGAAGVILWGDAGFTTSNETCRRLKDYLTRSLVPYVVNVSWAAQYCSWAQCHGHGRCVRRDPNAHTFLHLSASSFRLVPSHAPDEPRLRPEGELSWADRNHLQTHFRCQCYLGWGGEQCQWDRRRAAGGASGAWAGFHLTGLLAVAVLAFTWTS
|
| Molecular Weight | 53870.9 |
| Chemical Formula | C2455H3775N617O704S21 |
| Isoelectric Point | 5.73 |
| Hydrophobicity | -0.117 |
| Melting point | NA |
| Half-life | NA |
| Description | Highly purified sheep hyaluronidase for administration by injection into the vitreous of the eye. |
| Indication/Disease | For increase of absorption and distribution of other injected drugs and for rehydration. |
| Pharmacodynamics | Hyaluronidase hydrolyzes hyaluronic acid and increase diffusion of injected drugs, thus facilitating their absorption. Hyaluronidase is used for enhancing absorption and distribution of other injected drugs. |
| Mechanism of Action | Hyaluronidase is a spreading or diffusing substance. It increase the permeability of connective tissue through the hydrolysis of hyaluronic acid. Hyaluronidase hydrolyzes hyaluronic acid by splitting the glucosaminidic bond between C1 of the glucosamine moiety and C4 of glucuronic acid. This temporarily decreases the viscosity of the cellular cement and increases diffusion of injected fluids or of localized transudates or exudates, thus facilitating their absorption. |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| NA |
| Clearance | NA |
| Categories | Enzymes and Coenzymes |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | Hyaluronan,Transforming growth factor beta-1 |
| Brand Name | Vitrase |
| Company | Bausch & Lomb Incorporated |
| Brand Description | Bausch & Lomb Incorporated |
| Prescribed For | Subcutaneous |
| Chemical Name | 200 [USP'U]/1mL |
| Formulation | VITRASE (hyaluronidase injection) is contraindicated in patients with known hypersensitivity to hyaluronidase or any other ingredient in the formulation. A preliminary skin test for hypersensitivity to VITRASE can be performed. The skin test is made by intradermal injection of approximately 0.02 mL (4 Units) of a 200 Units/mL solution [see DOSAGE AND ADMINISTRATION]. A positive reaction consists of a wheal with pseudopods appearing within 5 minutes and persisting for 20 to 30 minutes and accompanied by localized itching. Transient vasodilation at the site of the test, i.e., erythema, is not a positive reaction. Discontinue VITRASE if sensitization occurs. |
| Physical Appearance | local injection site reactions such as pain, itching, redness, or swelling. |
| Route of Administration | NA |
| Recommended Dosage | Vitrase is a prescription medicine used to treat the symptoms of Hypodermoclysis, Extravasation, and Skin Test. Vitrase may be used alone or with other medications. |
| Contraindication | NA |
| Side Effects | VITRASE (hyaluronidase injection) is supplied as a sterile, non-preserved, colorless solution with a pH of 6.4 to 7.2. Each mL contains 200 USP units of ovine hyaluronidase with 0.93 mg lactose, 0.36 mg potassium phosphate dibasic, 0.23 mg potassium phosphate monobasic, and 9.0 mg sodium chloride. |
| Useful Link 1 | Link |
| Useful Link 2 | Link |
| Remarks | NA |